Health And Wellness Market News: FTC Settlement, FDA Alert, UK Ad Reviews

FTC settles with operators of a bogus cognitive supplement sales ring for $26.2m; FDA warns on unapproved at-home head injury tests; and UK advertising regulator says HiSmile claims fail, P&G Always Discreet claims pass.

The Federal Trade Commission settled with 12 corporate entities and four individual defendants marketing bogus cognitive supplement brands Geniux, Xcel, EVO and Ion-Z, using “sham” news sites containing false and unsubstantiated efficacy claims. The FTC announced that its complaint, filed in the US District Court for the Northern District of Ohio, alleges Fred Richard Guerra III, Lanty Paul Gray Jr. Rafat Abbas and Robby Salaheddine owned a web of corporate entities that between August 2012 and January 2017 sold the supplements for between $47 and $57 a bottle. False claims for products included that Geniux could “improve short- and long-term memory,” “increase focus” by as much as 300% and prevent memory loss. Claims were made on sites deceptively formatted as actual news sites. Some employed fake consumer endorsements and attributed the achievements of Stephen Hawking and Elon Musk to Geniux products.

The commission submitted two proposed orders settling the charges, one resolving allegations against Guerra, Gray and Abbas as well...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

HI-Wellness (Premium-1): Asthme et DT2 : une association qui dépasse le hasard

Des recherches montrent que l’asthme et le diabète de type 2 (DT2) sont liés au-delà du hasard, partageant des facteurs inflammatoires et métaboliques. Cette association souligne l’importance d’une surveillance accrue et d’une prise en charge adaptée pour prévenir les complications chez les patients

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Asking For More: Supplement MPL Authority For FDA, Agency Results For Congress, Industry

Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

 

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

More from Policy & Regulation

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

'Inside Regulatory Affairs' With The Honest Company’s Sharee Crumbey And Monica Sharda

 
• By 

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.